Pulse Biosciences, Inc. (PLSE)

Market Cap	1.30B +0.4%
Revenue (ttm)	751,000
Net Income	-74.57M
EPS	-1.10
Shares Out	68.23M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	201,686
Open	19.67
Previous Close	19.59
Day's Range	18.66 - 19.67
52-Week Range	12.56 - 26.30
Beta	1.63
Analysts	Buy
Price Target	22.00 (+15.3%)
Earnings Date	May 4, 2026

About PLSE

Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers nPulse System, a novel Nanosecond Pulsed-Field Ablation delivery platform to treat benign lesions of the skin; nPulse Vybrance Percutaneous Electrode system for soft tissue ablation in surgical setting; nPulse Cardiac Surgical Clamp designed for use in surgical treatment of atrial fibrillation (AF); nPulse Cardiac Catheter System designed to provide a circumferential, or circular, ablation in a single treatment cycle; and nPulse Console, a software-enabled conso...

• Industry: Medical Instruments & Supplies
• Sector: Healthcare
• IPO Date: May 18, 2016
• Employees: 116
• Stock Exchange: NASDAQ
• Ticker Symbol: PLSE
• Website: https://www.pulsebiosciences.com

Analyst Summary

According to one analyst, the rating for PLSE stock is "Buy" and the 12-month stock price target is $22.0.

Price Target

$22.0

(15.30% upside)

Analyst Consensus: Buy